immune system
• following Helicobacter pylori oral challenge
|
• H-Ala-D-g-Glu-diaminopimelic acid (DAP)- and muramyl dipeptide (MDP)-treated mice exhibit an increase in CCL2 (MCP-1) compared with similarly treated wild-type mice
• DAP-treated mice exhibit increased CCL3 (MIP-1alpha) compared with similarly treated wild-type mice
|
• in H-Ala-D-g-Glu-diaminopimelic acid (DAP)- and muramyl dipeptide (MDP)-treated mice
|
• in H-Ala-D-g-Glu-diaminopimelic acid (DAP)- and muramyl dipeptide (MDP)-treated mice
|
• following Helicobacter pylori oral challenge, mice exhibit increased infiltration of inflammatory cells in the gastric mucosa compared with wild-type mice
|
digestive/alimentary system
N |
• mice exhibit normal gastrointestinal tract development
|
• following oral challenge, mice exhibit reduced colonization by Helicobacter pylori and increased infiltration of inflammatory cells in the gastric mucosa compared with wild-type mice
|
• following Helicobacter pylori oral challenge
|
homeostasis/metabolism
• H-Ala-D-g-Glu-diaminopimelic acid (DAP)- and muramyl dipeptide (MDP)-treated mice exhibit an increase in CCL2 (MCP-1) compared with similarly treated wild-type mice
• DAP-treated mice exhibit increased CCL3 (MIP-1alpha) compared with similarly treated wild-type mice
|
• in H-Ala-D-g-Glu-diaminopimelic acid (DAP)- and muramyl dipeptide (MDP)-treated mice
|
• in H-Ala-D-g-Glu-diaminopimelic acid (DAP)- and muramyl dipeptide (MDP)-treated mice
|
hematopoietic system
N |
• mice exhibit normal hematopoiesis
|